Amicus Therapeutics Competitors

Amgen (NASDAQ:AMGN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Amgen and Amicus Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amgen and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amgen has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Amgen and Amicus Therapeutics, as reported by MarketBeat.com.

Amgen currently has a consensus price target of $254.08, suggesting a potential upside of 13.02%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Amicus Therapeutics.

Summary

Amgen beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Gilead Sciences and Amicus Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Gilead Sciences and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Gilead Sciences and Amicus Therapeutics, as reported by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $76.1538, suggesting a potential upside of 26.86%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Gilead Sciences' higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Amicus Therapeutics.

Summary

Gilead Sciences beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Vertex Pharmaceuticals and Amicus Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Vertex Pharmaceuticals and Amicus Therapeutics, as reported by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, suggesting a potential upside of 28.18%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Vertex Pharmaceuticals' higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amicus Therapeutics.

Summary

Vertex Pharmaceuticals beats Amicus Therapeutics on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Regeneron Pharmaceuticals and Amicus Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Regeneron Pharmaceuticals and Amicus Therapeutics, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus price target of $628.52, suggesting a potential upside of 22.27%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amicus Therapeutics.

Summary

Regeneron Pharmaceuticals beats Amicus Therapeutics on 12 of the 15 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Amicus Therapeutics and Biogen, as reported by MarketBeat.

Amicus Therapeutics currently has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Biogen has a consensus price target of $305.9032, suggesting a potential upside of 25.48%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Amicus Therapeutics.

Profitability

This table compares Amicus Therapeutics and Biogen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

78.9% of Biogen shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amicus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Valuation and Earnings

This table compares Amicus Therapeutics and Biogen's top-line revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Amicus Therapeutics and Seagen, as reported by MarketBeat.

Amicus Therapeutics currently has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Seagen has a consensus price target of $176.75, suggesting a potential upside of 4.51%. Given Seagen's higher probable upside, analysts plainly believe Seagen is more favorable than Amicus Therapeutics.

Profitability

This table compares Amicus Therapeutics and Seagen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.0% of Seagen shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by insiders. Comparatively, 31.1% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amicus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amicus Therapeutics and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Seagen has higher revenue and earnings than Amicus Therapeutics. Seagen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Amicus Therapeutics on 11 of the 15 factors compared between the two stocks.